Scheinberg, Tahlia http://orcid.org/0000-0003-4539-6216
Lin, Hui-Ming http://orcid.org/0000-0003-4892-6008
Fitzpatrick, Michael http://orcid.org/0000-0001-5797-6854
Azad, Arun A. http://orcid.org/0000-0001-7350-5622
Bonnitcha, Paul
Davies, Amy
Heller, Gillian http://orcid.org/0000-0003-1270-1499
Huynh, Kevin
Mak, Blossom http://orcid.org/0000-0003-3068-2498
Mahon, Kate
Sullivan, David
Meikle, Peter J. http://orcid.org/0000-0002-2593-4665
Horvath, Lisa G. http://orcid.org/0000-0001-6842-9223
Article History
Received: 15 November 2022
Revised: 23 March 2023
Accepted: 30 March 2023
First Online: 5 May 2023
Competing interests
: This work has been filed for provisional patent application (Application number 2022902527, application date 2 September 2022, Applicant name Lifehouse Australia, Baker Heart and Diabetes Institute, Tahlia Scheinberg).
: All participants gave written informed consent for the study (Monash Health Institutional Review Board (15571X), Royal Prince Alfred Hospital Human Research Ethics Committee (X14-0406, X19-0320), Australia-New Zealand Clinical Trials Registry ACTRN12607000077460, ACTRN12611000540910).